Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EBIT (2023 - 2025)

NewAmsterdam Pharma's EBIT history spans 3 years, with the latest figure at $107.1 million for Q4 2025.

  • For Q4 2025, EBIT rose 347.79% year-over-year to $107.1 million; the TTM value through Dec 2025 reached -$52.6 million, up 70.17%, while the annual FY2025 figure was -$52.6 million, 70.17% up from the prior year.
  • EBIT for Q4 2025 was $107.1 million at NewAmsterdam Pharma, up from -$55.1 million in the prior quarter.
  • Across five years, EBIT topped out at $107.1 million in Q4 2025 and bottomed at -$68.9 million in Q1 2025.
  • The 3-year median for EBIT is -$46.4 million (2023), against an average of -$34.3 million.
  • The largest YoY upside for EBIT was 347.79% in 2025 against a maximum downside of 120.55% in 2025.
  • A 3-year view of EBIT shows it stood at -$51.1 million in 2023, then grew by 15.36% to -$43.2 million in 2024, then skyrocketed by 347.79% to $107.1 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's EBIT are $107.1 million (Q4 2025), -$55.1 million (Q3 2025), and -$35.6 million (Q2 2025).